目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Objectives of secondary research
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation
2.2.1.2 Approach 2: Customer-based market estimation
2.2.1.3 Approach 3: Primary interviews
2.2.2 TOP-DOWN APPROACH
2.3 GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 DERMA FILLERS MARKET OVERVIEW
4.2 NORTH AMERICA: DERMA FILLERS MARKET, BY PROCEDURE, 2025 VS. 2030 (USD MILLION)
4.3 EUROPE: DERMA FILLERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.4 DERMA FILLERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing adoption of minimally invasive and non-invasive aesthetic procedures
5.2.1.2 Growing demand for aesthetic treatments among elderly and men
5.2.1.3 Rising acceptance and normalization of fillers among millennials and Gen Z fueled by social media
5.2.2 RESTRAINTS
5.2.2.1 Risk of infection and safety concerns
5.2.2.2 Complex regulatory framework and compliance standards
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.3.2 Launch of new technologies and products
5.2.4 CHALLENGES
5.2.4.1 High cost of treatments and devices
5.2.4.2 Social and cultural barriers
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 RAW MATERIAL PROCUREMENT AND PRODUCT MANUFACTURING
5.5.3 DISTRIBUTION, MARKETING & SALES, AND AFTER-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Advanced Hyaluronic Acid (HA) cross-linking
5.9.1.2 Polymethylmethacrylate (PMMA) fillers
5.9.1.3 Bio-stimulatory fillers
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Laser resurfacing
5.9.2.2 Microneedling
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 3D imaging and AI-based facial mapping
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT SCENARIO (HS CODE 330499)
5.11.2 EXPORT SCENARIO (HS CODE 330499)
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 COMMERCIAL PARTNERSHIPS FOR AESTHETIC PRODUCT SALES
5.13.2 DIVERSIFICATION OF BUSINESS TO MEET CUSTOMER DEMANDS
5.13.3 COLLABORATIONS WITH SMES FOR STREAMLINING LASER-BASED DEVICES
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 UK
5.14.1.2.2 France
5.14.1.2.3 Germany
5.14.1.3 Asia Pacific
5.14.1.3.1 Japan
5.14.1.3.2 India
5.14.1.4 Rest of the World
5.14.1.4.1 Brazil
5.14.1.4.2 UAE
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 BUYING CRITERIA
5.17 REIMBURSEMENT SCENARIO
5.18 UNMET NEEDS AND KEY PAIN POINTS
5.19 IMPACT OF AI ON DERMA FILLERS MARKET
5.19.1 INTRODUCTION
5.19.2 MARKET POTENTIAL OF AI ON DERMA FILLERS ECOSYSTEM
5.19.3 AI USE CASES
5.19.4 KEY COMPANIES IMPLEMENTING AI
5.19.5 FUTURE OF GENERATIVE AI IN DERMA FILLERS MARKET
5.20 US TARIFF 2025
5.20.1 INTRODUCTION
5.20.2 KEY TARIFF RATES
5.20.3 PRICE IMPACT ANALYSIS
5.20.4 IMPACT ON COUNTRY/REGION
5.20.4.1 US
5.20.4.2 Europe
5.20.4.3 Asia Pacific
5.20.5 IMPACT ON END-USE INDUSTRIES

6 DERMA FILLERS MARKET, BY BRAND
6.1 INTRODUCTION
6.2 JUVEDERM
6.2.1 WIDE INDICATION COVERAGE AND GLOBAL REACH TO CONTRIBUTE TO GROWTH
6.3 RESTYLANE
6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT TO ENCOURAGE GROWTH
6.4 RHA COLLECTION
6.4.1 GROWING DESIRE FOR NATURAL EXPRESSIONS TO BOOST MARKET
6.5 SCULPTRA
6.5.1 INCREASED ADOPTION OF SCULPTRA AMONG ADVANCED INJECTORS TO BOLSTER GROWTH
6.6 RADIESSE
6.6.1 STABLE SUCCESS RATES AND DESIRED RESULTS TO SPUR GROWTH
6.7 LANLUMA
6.7.1 EXPANDED USE CASES IN BODY CONTOURING APPLICATIONS TO INTENSIFY GROWTH
6.8 BELLAFILL
6.8.1 USE OF BELLAFILL FOR TREATING DEEP ACNE SCARS AND NASOLABIAL FOLDS TO FOSTER GROWTH
6.9 OTHER BRANDS

7 DERMA FILLERS MARKET, BY PRODUCT TYPE
7.1 INTRODUCTION
7.2 NATURAL DERMAL FILLERS
7.2.1 HYALURONIC ACID FILLERS
7.2.1.1 Wide clinical acceptance and safety profile to aid growth
7.2.2 COLLAGEN FILLERS
7.2.2.1 Ability to provide structural support and improved skin texture to boost market
7.3 SYNTHETIC DERMAL FILLERS
7.3.1 CALCIUM HYDROXYLAPATITE (CAHA) FILLERS
7.3.1.1 Long-term collagen stimulation property to augment growth
7.3.2 POLY-L-LACTIC ACID (PLLA) FILLERS
7.3.2.1 Increasing desire for natural, progressive rejuvenation to stimulate growth
7.3.3 POLYMETHYL METHACRYLATE (PMMA) FILLERS
7.3.3.1 Long-lasting structural correction ability to favor growth
7.3.4 POLYNUCLEOTIDE FILLERS
7.3.4.1 Rising preference for skin revitalization procedures to fuel market
7.3.5 OTHER SYNTHETIC FILLERS

8 DERMA FILLERS MARKET, BY PROCEDURE
8.1 INTRODUCTION
8.2 SKIN REJUVENATION
8.2.1 INCREASING ACCEPTANCE AND REPEATABILITY OF SKIN PROCEDURES TO FACILITATE GROWTH
8.3 FACE & BODY CONTOURING
8.3.1 RISING NUMBER OF FACIAL AND BODY CONTOURING-RELATED PROCEDURES TO PROMOTE GROWTH
8.4 LIP AUGMENTATION
8.4.1 NEED FOR REPETITIVE CYCLES TO MAINTAIN DESIRED LOOK TO PROPEL MARKET
8.5 OTHER PROCEDURES

9 DERMA FILLERS MARKET, BY END USER
9.1 INTRODUCTION
9.2 DERMATOLOGY CLINICS & HOSPITALS
9.2.1 RISING TREND OF MEDICAL TOURISM AND PLASTIC SURGERY TO SUPPORT GROWTH
9.3 BEAUTY CENTERS
9.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENT TO DRIVE MARKET
9.4 MEDICAL SPAS
9.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST SAVING TO SPUR GROWTH
9.5 OTHER END USERS

10 DERMA FILLERS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Rising geriatric population to spur growth
10.2.3 CANADA
10.2.3.1 Preference of aging individuals to reduce aging signs to promote growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Large consumer base to expedite growth
10.3.3 UK
10.3.3.1 Increasing volume-enhancement treatments to support growth
10.3.4 FRANCE
10.3.4.1 Favorable demographics and increased acceptance of non-surgical procedures to aid growth
10.3.5 ITALY
10.3.5.1 Growing acceptance of minimally invasive procedures to fuel market
10.3.6 SPAIN
10.3.6.1 Increasing availability of safe and minimally invasive treatments to augment growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 JAPAN
10.4.2.1 Growing trend of volume restoration and wrinkle correction to boost market
10.4.3 CHINA
10.4.3.1 Surging demand for aesthetic procedures to accelerate growth
10.4.4 INDIA
10.4.4.1 Rapid urbanization and proliferation of clinics to stimulate growth
10.4.5 AUSTRALIA
10.4.5.1 Rising safety standards for non-surgical cosmetic procedures to encourage growth
10.4.6 SOUTH KOREA
10.4.6.1 Robust medical infrastructure to speed up growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Cultural normalization of aesthetic treatments to contribute to growth
10.5.3 MEXICO
10.5.3.1 Increasing inflow of medical tourists to sustain growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2 GCC COUNTRIES
10.6.2.1 Booming aesthetic tourism sector to facilitate growth
10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.4.1 NATURAL DERMA FILLERS MARKET SHARE
11.4.2 SYNTHETIC DERMAL FILLERS MARKET SHARE
11.5 COMPANY VALUATION AND FINANCIAL METRICS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.7.1 STARS
11.7.2 EMERGING LEADERS
11.7.3 PERVASIVE PLAYERS
11.7.4 PARTICIPANTS
11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.7.5.1 Company footprint
11.7.5.2 Region footprint
11.7.5.3 Product type footprint
11.7.5.4 Procedure footprint
11.7.5.5 End-user footprint
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.8.1 PROGRESSIVE COMPANIES
11.8.2 RESPONSIVE COMPANIES
11.8.3 DYNAMIC COMPANIES
11.8.4 STARTING BLOCKS
11.8.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.8.5.1 Detailed list of key startups/SMEs
11.8.5.2 Competitive benchmarking of key startups/SMEs
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES AND APPROVALS
11.9.2 DEALS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 ABBVIE INC.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches and approvals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 GALDERMA
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches and approvals
12.1.2.3.2 Deals
12.1.2.3.3 Expansions
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 MERZ PHARMA
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Expansions
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 SILCLAIR PHARMA
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 MnM view
12.1.4.3.1 Key strengths
12.1.4.3.2 Strategic choices
12.1.4.3.3 Weaknesses and competitive threats
12.1.5 REVANCE
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches and approvals
12.1.5.3.2 Deals
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 CROMA PHARMA
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 EVOLUS, INC.
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches and approvals
12.1.8 HUGEL, INC.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 MEDYTOX
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 BIOXIS PHARMACEUTICAL
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 ZIMMER MEDIZINSYSTEME GMBH
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 CUTERA, INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches and approvals
12.1.12.3.2 Deals
12.1.13 SCIVISION BIOTECH INC.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 BRIDGEPOINT GROUP PLC
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 ANIKA THERAPEUTICS, INC.
12.1.15.1 Business overview
12.1.15.2 Products offered
12.2 OTHER PLAYERS
12.2.1 TIGER AESTHETICS MEDICAL
12.2.2 PROLLENIUM MEDICAL TECHNOLOGIES
12.2.3 BIOSCIENCE GMBH
12.2.4 DERMAX
12.2.5 TEOXANE
12.2.6 DR. KORMAN LABORATORIES LTD.
12.2.7 CYTOPHIL, INC.
12.2.8 TELETA PHARMA
12.2.9 IBSA DERMA
12.2.10 NEOGENESIS
12.2.11 CGBIO, CO., LTD.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS